{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:17:49Z","timestamp":1792844269400,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["219639\/Z\/19\/Z"],"award-info":[{"award-number":["219639\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["219639\/Z\/19\/Z"],"award-info":[{"award-number":["219639\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1117400"],"award-info":[{"award-number":["OPP1117400"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1117400"],"award-info":[{"award-number":["OPP1117400"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1117400"],"award-info":[{"award-number":["OPP1117400"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-024-01810-x","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:18:43Z","timestamp":1728382723000},"page":"2817-2835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-9303","authenticated-orcid":false,"given":"Ujjini H.","family":"Manjunatha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-3147","authenticated-orcid":false,"given":"Suresh B.","family":"Lakshminarayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv S.","family":"Jumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Gable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Rene","family":"Galarneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Cantwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upendra","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peichao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen H.","family":"Darrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1907-768X","authenticated-orcid":false,"given":"Lucy C.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4343-4645","authenticated-orcid":false,"given":"Debjani","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulugeta","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cuellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Shaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K.","family":"Carney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lakshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin S.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Zambriski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8195-1446","authenticated-orcid":false,"given":"Natasha","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-5683","authenticated-orcid":false,"given":"Thierry T.","family":"Diagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"1810_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S1473-3099(18)30362-1","volume":"18","author":"GBD 2016 Diarrhoeal Disease Collaborators.","year":"2018","unstructured":"GBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 18, 1211\u20131228 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1810_CR2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S0016-5085(76)80331-9","volume":"70","author":"JL Meisel","year":"1976","unstructured":"Meisel, J. L., Perera, D. R., Meligro, C. & Rubin, C. E. Overwhelming watery diarrhea associated with a Cryptosporidium in an immunosuppressed patient. Gastroenterology 70, 1156\u20131160 (1976).","journal-title":"Gastroenterology"},{"key":"1810_CR3","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1093\/cid\/ciad044","volume":"76","author":"MJ Hossain","year":"2023","unstructured":"Hossain, M. J. et al. Clinical and epidemiologic features of Cryptosporidium-associated diarrheal disease among young children living in Sub-Saharan Africa: the Vaccine Impact on Diarrhea in Africa (VIDA) study. Clin. Infect. Dis. 76, S97\u2013S105 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"1810_CR4","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/S2214-109X(19)30076-2","volume":"7","author":"KL Kotloff","year":"2019","unstructured":"Kotloff, K. L. et al. The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS). Lancet Glob. Health 7, e568\u2013e584 (2019).","journal-title":"Lancet Glob. Health"},{"key":"1810_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","volume":"382","author":"KL Kotloff","year":"2013","unstructured":"Kotloff, K. L. et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382, 209\u2013222 (2013).","journal-title":"Lancet"},{"key":"1810_CR6","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/S2214-109X(15)00151-5","volume":"3","author":"JA Platts-Mills","year":"2015","unstructured":"Platts-Mills, J. A. et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob. Health 3, e564\u2013e575 (2015).","journal-title":"Lancet Glob. Health"},{"key":"1810_CR7","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2214-109X(18)30283-3","volume":"6","author":"IA Khalil","year":"2018","unstructured":"Khalil, I. A. et al. Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. Lancet Glob. Health 6, e758\u2013e768 (2018).","journal-title":"Lancet Glob. Health"},{"key":"1810_CR8","doi-asserted-by":"publisher","first-page":"e0004729","DOI":"10.1371\/journal.pntd.0004729","volume":"10","author":"SO Sow","year":"2016","unstructured":"Sow, S. O. et al. The burden of Cryptosporidium diarrheal disease among children <24 months of age in moderate\/high mortality regions of Sub-Saharan Africa and South Asia, utilizing data from the Global Enteric Multicenter Study (GEMS). PLoS Negl. Trop. Dis. 10, e0004729 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1810_CR9","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1093\/aje\/kwy106","volume":"187","author":"AE Schnee","year":"2018","unstructured":"Schnee, A. E. et al. Identification of etiology-specific diarrhea associated with linear growth faltering in Bangladeshi infants. Am. J. Epidemiol. 187, 2210\u20132218 (2018).","journal-title":"Am. J. Epidemiol."},{"key":"1810_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4269\/ajtmh.1999.61.707","volume":"61","author":"DI Guerrant","year":"1999","unstructured":"Guerrant, D. I. et al. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. Am. J. Trop. Med. Hyg. 61, 707\u2013713 (1999).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1810_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4269\/ajtmh.2009.80.824","volume":"80","author":"D Mondal","year":"2009","unstructured":"Mondal, D., Haque, R., Sack, R. B., Kirkpatrick, B. D. & Petri, W. A. Attribution of malnutrition to cause-specific diarrheal illness: evidence from a prospective study of preschool children in Mirpur, Dhaka, Bangladesh. Am. J. Trop. Med. Hyg. 80, 824\u2013826 (2009).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1810_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1128\/IAI.01237-06","volume":"75","author":"HC Wang","year":"2007","unstructured":"Wang, H. C. et al. High levels of CXCL10 are produced by intestinal epithelial cells in AIDS patients with active cryptosporidiosis but not after reconstitution of immunity. Infect. Immun. 75, 481\u2013487 (2007).","journal-title":"Infect. Immun."},{"key":"1810_CR13","first-page":"1","volume":"64","author":"JE Painter","year":"2015","unstructured":"Painter, J. E. et al. Cryptosporidiosis surveillance\u2014United States, 2011\u20132012. MMWR Suppl. 64, 1\u201314 (2015).","journal-title":"MMWR Suppl."},{"key":"1810_CR14","doi-asserted-by":"crossref","unstructured":"Mora, C. et al. Over half of known human pathogenic diseases can be aggravated by climate change. Nat. Clim. Change 12, 869\u2013875 (2022).","DOI":"10.1038\/s41558-022-01426-1"},{"key":"1810_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","volume":"15","author":"W Checkley","year":"2015","unstructured":"Checkley, W. et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium. Lancet Infect. Dis. 15, 85\u201394 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"1810_CR16","doi-asserted-by":"publisher","first-page":"e0009057","DOI":"10.1371\/journal.pntd.0009057","volume":"15","author":"PG Ashigbie","year":"2021","unstructured":"Ashigbie, P. G. et al. Use-case scenarios for an anti-Cryptosporidium therapeutic. PLoS Negl. Trop. Dis. 15, e0009057 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1810_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","volume":"360","author":"B Amadi","year":"2002","unstructured":"Amadi, B. et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375\u20131380 (2002).","journal-title":"Lancet"},{"key":"1810_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-195","volume":"2","author":"BM Amadi","year":"2009","unstructured":"Amadi, B. M. et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect. Dis. 2, 195 (2009).","journal-title":"BMC Infect. Dis."},{"key":"1810_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012540","volume":"8","author":"IH Gilbert","year":"2023","unstructured":"Gilbert, I. H. et al. Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease. BMJ Glob. Health 8, e012540 (2023).","journal-title":"BMJ Glob. Health"},{"key":"1810_CR20","doi-asserted-by":"publisher","first-page":"e3001604","DOI":"10.1371\/journal.pbio.3001604","volume":"20","author":"ED English","year":"2022","unstructured":"English, E. D., Guerin, A., Tandel, J. & Striepen, B. Live imaging of the Cryptosporidium parvum life cycle reveals direct development of male and female gametes from type I meronts. PLoS Biol. 20, e3001604 (2022).","journal-title":"PLoS Biol."},{"key":"1810_CR21","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/cid\/ciad059","volume":"76","author":"P Korpe","year":"2023","unstructured":"Korpe, P. et al. Prospective cohort study of Cryptosporidium infection and shedding in infants and their households. Clin. Infect. Dis. 76, 2178\u20132186 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"1810_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02741-21","volume":"10","author":"OH Johansen","year":"2022","unstructured":"Johansen, O. H. et al. Oocyst shedding dynamics in children with cryptosporidiosis: a prospective clinical case series in Ethiopia. Microbiol. Spectr. 10, e0274121 (2022).","journal-title":"Microbiol. Spectr."},{"key":"1810_CR23","doi-asserted-by":"publisher","first-page":"e0009643","DOI":"10.1371\/journal.pntd.0009643","volume":"15","author":"PY Iroh Tam","year":"2021","unstructured":"Iroh Tam, P. Y., Chisala, M., Nyangulu, W., Thole, H. & Nyirenda, J. Respiratory cryptosporidiosis in Malawian children with diarrheal disease. PLoS Negl. Trop. Dis. 15, e0009643 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1810_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature22337","volume":"546","author":"UH Manjunatha","year":"2017","unstructured":"Manjunatha, U. H. et al. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature 546, 376\u2013380 (2017).","journal-title":"Nature"},{"key":"1810_CR25","unstructured":"First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers (ClinicalTrials.gov, 2023); https:\/\/ClinicalTrials.gov\/show\/NCT05275855"},{"key":"1810_CR26","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1073\/pnas.1814685116","volume":"116","author":"B Baragana","year":"2019","unstructured":"Baragana, B. et al. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proc. Natl Acad. Sci. USA 116, 7015\u20137020 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1810_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba8412","volume":"12","author":"S Vinayak","year":"2020","unstructured":"Vinayak, S. et al. Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Sci. Transl. Med. 12, eaba8412 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1810_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jix247","volume":"216","author":"SLM Arnold","year":"2017","unstructured":"Arnold, S. L. M. et al. Necessity of bumped kinase inhibitor gastrointestinal exposure in treating Cryptosporidium infection. J. Infect. Dis. 216, 55\u201363 (2017).","journal-title":"J. Infect. Dis."},{"key":"1810_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/17425255.2020.1777280","volume":"16","author":"P Buchwald","year":"2020","unstructured":"Buchwald, P. Soft drugs: design principles, success stories, and future perspectives. Expert Opin. Drug Metab. Toxicol. 16, 645\u2013650 (2020).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1810_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1389200219666180821094502","volume":"20","author":"L Di","year":"2019","unstructured":"Di, L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr. Drug Metab. 20, 91\u2013102 (2019).","journal-title":"Curr. Drug Metab."},{"key":"1810_CR31","unstructured":"Young, J. M., Turner, M. R. & Lu, P. Compounds and compositions for the treatment of cryptosporidiosis. US patent 12,018,024 B2 (assigned to Novartis AG) (2022)."},{"key":"1810_CR32","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1002\/jps.23258","volume":"101","author":"FG Bahar","year":"2012","unstructured":"Bahar, F. G., Ohura, K., Ogihara, T. & Imai, T. Species difference of esterase expression and hydrolase activity in plasma. J. Pharm. Sci. 101, 3979\u20133988 (2012).","journal-title":"J. Pharm. Sci."},{"key":"1810_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-3-030-50621-6_9","volume":"1274","author":"JA McPhail","year":"2020","unstructured":"McPhail, J. A. & Burke, J. E. Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral\/parasitic infections. Adv. Exp. Med. Biol. 1274, 203\u2013222 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1810_CR34","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1126\/science.1253397","volume":"344","author":"JE Burke","year":"2014","unstructured":"Burke, J. E. et al. Structures of PI4KIIIbeta complexes show simultaneous recruitment of Rab11 and its effectors. Science 344, 1035\u20131038 (2014).","journal-title":"Science"},{"key":"1810_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09880-w","volume":"10","author":"RS Jumani","year":"2019","unstructured":"Jumani, R. S. et al. A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors. Nat. Commun. 10, 1862 (2019).","journal-title":"Nat. Commun."},{"key":"1810_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00052-20","volume":"11","author":"LJ Funkhouser-Jones","year":"2020","unstructured":"Funkhouser-Jones, L. J., Ravindran, S. & Sibley, L. D. Defining stage-specific activity of potent new inhibitors of Cryptosporidium parvum growth in vitro. mBio 11, e00052-20 (2020).","journal-title":"mBio"},{"key":"1810_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature12782","volume":"504","author":"CW McNamara","year":"2013","unstructured":"McNamara, C. W. et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248\u2013253 (2013).","journal-title":"Nature"},{"key":"1810_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01505-17","volume":"62","author":"RS Jumani","year":"2018","unstructured":"Jumani, R. S. et al. A novel piperazine-based drug lead for cryptosporidiosis from the Medicines for Malaria Venture Open-access Malaria Box. Antimicrob. Agents Chemother. 62, e01505-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1810_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/gut.45.1.70","volume":"45","author":"D Sharpstone","year":"1999","unstructured":"Sharpstone, D. et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 45, 70\u201376 (1999).","journal-title":"Gut"},{"key":"1810_CR40","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.2174\/138161212799504858","volume":"18","author":"D Charmot","year":"2012","unstructured":"Charmot, D. Non-systemic drugs: a critical review. Curr. Pharm. Des. 18, 1434\u20131445 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"1810_CR41","unstructured":"Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (US Food and Drug Administration, 2010)."},{"key":"1810_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.exppara.2009.03.018","volume":"124","author":"L Xiao","year":"2010","unstructured":"Xiao, L. Molecular epidemiology of cryptosporidiosis: an update. Exp. Parasitol. 124, 80\u201389 (2010).","journal-title":"Exp. Parasitol."},{"key":"1810_CR43","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/cmi.12285","volume":"16","author":"CR Harding","year":"2014","unstructured":"Harding, C. R. & Meissner, M. The inner membrane complex through development of Toxoplasma gondii and Plasmodium. Cell. Microbiol. 16, 632\u2013641 (2014).","journal-title":"Cell. Microbiol."},{"key":"1810_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00023-21","volume":"65","author":"MM Hasan","year":"2021","unstructured":"Hasan, M. M. et al. Spontaneous selection of Cryptosporidium drug resistance in a calf model of infection. Antimicrob. Agents Chemother. 65, e00023-21 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1810_CR45","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.4269\/ajtmh.17-0741","volume":"98","author":"SM Mor","year":"2018","unstructured":"Mor, S. M. et al. Expectoration of Cryptosporidium parasites in sputum of human immunodeficiency virus-positive and -negative adults. Am. J. Trop. Med. Hyg. 98, 1086\u20131090 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1810_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1021\/acsmedchemlett.3c00001","volume":"14","author":"R Dorel","year":"2023","unstructured":"Dorel, R., Wong, A. R. & Crawford, J. J. Trust your gut: strategies and tactics for intestinally restricted drugs. ACS Med. Chem. Lett. 14, 233\u2013243 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"1810_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1586\/14787210.3.2.201","volume":"3","author":"L Gerard","year":"2005","unstructured":"Gerard, L., Garey, K. W. & DuPont, H. L. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev. Anti Infect. Ther. 3, 201\u2013211 (2005).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"1810_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/acs.jmedchem.6b01465","volume":"60","author":"I Mejdrova","year":"2017","unstructured":"Mejdrova, I. et al. Rational design of novel highly potent and selective phosphatidylinositol 4-kinase IIIbeta (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology. J. Med. Chem. 60, 100\u2013118 (2017).","journal-title":"J. Med. Chem."},{"key":"1810_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature14651","volume":"523","author":"S Vinayak","year":"2015","unstructured":"Vinayak, S. et al. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature 523, 477\u2013480 (2015).","journal-title":"Nature"},{"key":"1810_CR50","doi-asserted-by":"publisher","first-page":"20B.2.1","DOI":"10.1002\/cpmc.33","volume":"46","author":"MC Pawlowic","year":"2017","unstructured":"Pawlowic, M. C., Vinayak, S., Sateriale, A., Brooks, C. F. & Striepen, B. Generating and maintaining transgenic Cryptosporidium parvum parasites. Curr. Protoc. Microbiol. 46, 20B.2.1\u201320B.2.32 (2017).","journal-title":"Curr. Protoc. Microbiol."},{"key":"1810_CR51","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1021\/acsinfecdis.7b00247","volume":"4","author":"AT Chao","year":"2018","unstructured":"Chao, A. T. et al. Development of a cytopathic effect-based phenotypic screening assay against Cryptosporidium. ACS Infect. Dis. 4, 635\u2013645 (2018).","journal-title":"ACS Infect. Dis."},{"key":"1810_CR52","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/2472555217752140","volume":"23","author":"H Gubler","year":"2018","unstructured":"Gubler, H. et al. Helios: history and anatomy of a successful in-house enterprise high-throughput screening and profiling data analysis system. SLAS Discov. 23, 474\u2013488 (2018).","journal-title":"SLAS Discov."},{"key":"1810_CR53","doi-asserted-by":"publisher","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","volume":"11","author":"MS Love","year":"2017","unstructured":"Love, M. S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl. Trop. Dis. 11, e0005373 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1810_CR54","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/pro.2879","volume":"25","author":"ML Fowler","year":"2016","unstructured":"Fowler, M. L. et al. Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: case study of PI4KIIIbeta with Rab11. Protein Sci. 25, 826\u2013839 (2016).","journal-title":"Protein Sci."},{"key":"1810_CR55","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","volume":"429","author":"Y Lu","year":"2017","unstructured":"Lu, Y. et al. Rationally designed PI3Kalpha mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors. J. Mol. Biol. 429, 1684\u20131704 (2017).","journal-title":"J. Mol. Biol."},{"key":"1810_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-61779-520-6_6","volume":"841","author":"P Emsley","year":"2012","unstructured":"Emsley, P. & Debreczeni, J. E. The use of molecular graphics in structure-based drug design. Methods Mol. Biol. 841, 143\u2013159 (2012).","journal-title":"Methods Mol. Biol."},{"key":"1810_CR57","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1002\/jps.20913","volume":"96","author":"L Zhou","year":"2007","unstructured":"Zhou, L., Yang, L., Tilton, S. & Wang, J. Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. J. Pharm. Sci. 96, 3052\u20133071 (2007).","journal-title":"J. Pharm. Sci."},{"key":"1810_CR58","doi-asserted-by":"publisher","first-page":"886","DOI":"10.2174\/138920008786485227","volume":"9","author":"B Faller","year":"2008","unstructured":"Faller, B. Artificial membrane assays to assess permeability. Curr. Drug Metab. 9, 886\u2013892 (2008).","journal-title":"Curr. Drug Metab."},{"key":"1810_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1021\/js9803205","volume":"88","author":"JD Irvine","year":"1999","unstructured":"Irvine, J. D. et al. MDCK (Madin\u2013Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88, 28\u201333 (1999).","journal-title":"J. Pharm. Sci."},{"key":"1810_CR60","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1023\/A:1020765025857","volume":"19","author":"YY Lau","year":"2002","unstructured":"Lau, Y. Y. et al. The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios. Pharm. Res. 19, 1606\u20131610 (2002).","journal-title":"Pharm. Res."},{"key":"1810_CR61","first-page":"1350","volume":"27","author":"RS Obach","year":"1999","unstructured":"Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27, 1350\u20131359 (1999).","journal-title":"Drug Metab. Dispos."},{"key":"1810_CR62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijpharm.2005.03.022","volume":"297","author":"L Di","year":"2005","unstructured":"Di, L., Kerns, E. H., Hong, Y. & Chen, H. Development and application of high throughput plasma stability assay for drug discovery. Int. J. Pharm. 297, 110\u2013119 (2005).","journal-title":"Int. J. Pharm."},{"key":"1810_CR63","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1002\/jps.21317","volume":"97","author":"NJ Waters","year":"2008","unstructured":"Waters, N. J., Jones, R., Williams, G. & Sohal, B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci. 97, 4586\u20134595 (2008).","journal-title":"J. Pharm. Sci."},{"key":"1810_CR64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/1087057108317480","volume":"13","author":"L Bell","year":"2008","unstructured":"Bell, L. et al. Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. J. Biomol. Screen. 13, 343\u2013353 (2008).","journal-title":"J. Biomol. Screen."},{"key":"1810_CR65","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1124\/dmd.110.037911","volume":"39","author":"A Zimmerlin","year":"2011","unstructured":"Zimmerlin, A., Trunzer, M. & Faller, B. CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab. Dispos. 39, 1039\u20131046 (2011).","journal-title":"Drug Metab. Dispos."},{"key":"1810_CR66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1517\/17425255.3.5.641","volume":"3","author":"J Wang","year":"2007","unstructured":"Wang, J., Urban, L. & Bojanic, D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin. Drug Metab. Toxicol. 3, 641\u2013665 (2007).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1810_CR67","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/17425255.2.6.823","volume":"2","author":"B Faller","year":"2006","unstructured":"Faller, B. et al. High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis. Expert Opin. Drug Metab. Toxicol. 2, 823\u2013833 (2006).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1810_CR68","unstructured":"Test No. 432: In Vitro 3T3 NRU Phototoxicity Test (OECD, 2019)."},{"key":"1810_CR69","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1073\/pnas.70.3.782","volume":"70","author":"BN Ames","year":"1973","unstructured":"Ames, B. N., Lee, F. D. & Durston, W. E. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc. Natl Acad. Sci. USA 70, 782\u2013786 (1973).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1810_CR70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/em.20632","volume":"52","author":"M Lukamowicz","year":"2011","unstructured":"Lukamowicz, M., Woodward, K., Kirsch-Volders, M., Suter, W. & Elhajouji, A. A flow cytometry based in vitro micronucleus assay in TK6 cells\u2013validation using early stage pharmaceutical development compounds. Environ. Mol. Mutagen. 52, 363\u2013372 (2011).","journal-title":"Environ. Mol. Mutagen."},{"key":"1810_CR71","unstructured":"Test No. 487: In Vitro Mammalian Cell Micronucleus Test (OECD, 2016)."},{"key":"1810_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mrgentox.2006.08.004","volume":"626","author":"Z Cammerer","year":"2007","unstructured":"Cammerer, Z., Elhajouji, A. & Suter, W. In vivo micronucleus test with flow cytometry after acute and chronic exposures of rats to chemicals. Mutat. Res. 626, 26\u201333 (2007).","journal-title":"Mutat. Res."},{"key":"1810_CR73","unstructured":"Test No. 489: In Vivo Mammalian Alkaline Comet Assay (OECD, 2016)."},{"key":"1810_CR74","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1099\/jmm.0.2008\/001461-0","volume":"57","author":"N Jothikumar","year":"2008","unstructured":"Jothikumar, N., da Silva, A. J., Moura, I., Qvarnstrom, Y. & Hill, V. R. Detection and differentiation of Cryptosporidium hominis and Cryptosporidium parvum by dual TaqMan assays. J. Med. Microbiol. 57, 1099\u20131105 (2008).","journal-title":"J. Med. Microbiol."},{"key":"1810_CR75","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1645\/GE-2475.1","volume":"97","author":"ML Bellosa","year":"2011","unstructured":"Bellosa, M. L. et al. A comparison of fecal percent dry matter and number of Cryptosporidium parvum oocysts shed to observational fecal consistency scoring in dairy calves. J. Parasitol. 97, 349\u2013351 (2011).","journal-title":"J. Parasitol."},{"key":"1810_CR76","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.vetpar.2013.04.022","volume":"197","author":"JA Zambriski","year":"2013","unstructured":"Zambriski, J. A. et al. Cryptosporidium parvum: determination of ID50 and the dose\u2013response relationship in experimentally challenged dairy calves. Vet. Parasitol. 197, 104\u2013112 (2013).","journal-title":"Vet. Parasitol."},{"key":"1810_CR77","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1128\/JCM.43.9.4551-4557.2005","volume":"43","author":"J Dreier","year":"2005","unstructured":"Dreier, J., Stormer, M. & Kleesiek, K. Use of bacteriophage MS2 as an internal control in viral reverse transcription-PCR assays. J. Clin. Microbiol. 43, 4551\u20134557 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"1810_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4269\/ajtmh.14-0488","volume":"92","author":"DJ Operario","year":"2015","unstructured":"Operario, D. J., Bristol, L. S., Liotta, J., Nydam, D. V. & Houpt, E. R. Correlation between diarrhea severity and oocyst count via quantitative PCR or fluorescence microscopy in experimental cryptosporidiosis in calves. Am. J. Trop. Med. Hyg. 92, 45\u201349 (2015).","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01810-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:05:34Z","timestamp":1730855134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-024-01810-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1038\/s41564-024-01810-x","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Multiple authors (U.H.M., S.B.L., R.S.J., A.T.C., J.M.Y., J.E.G., M.K., I.H., J.-R.G., J.C., U.K., M.T., P.L., K.H.D., K.C., D.P., M.M., C.L., C.C., J.S., L.X., Y.-B.C., J.L., C.S.O., N.A., C.S. and T.T.D.) are employees of Novartis and some of them have shares in the company. Compounds described in this report have been patented by Novartis, with J.M.Y., M.T. and P.L. listed as authors (US Patent WO\/2022\/079616). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}